Fig. 1 · Structure

Documents & Downloads

PF-3644022

Cat. No. A11282 CAS 1276121-88-0

MK2 Inhibitor

PF-3644022 is a potent and selective mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) inhibitor (Ki =3 nM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
MDCK IC50 7 μM Inhibition of MRP2 in MDCK cells after 15 mins by Calcein-AM assay [PMID: 26502061]
Sf9 IC50 7 μM Inhibition of human BSEP expressed in recombinant baculovirus infected insect Sf9 cell membrane vesicles assessed as [3H]-taurocholate transport preincubated for 5 mins followed by ATP or AMP addition measured after 5 mins by scintillation counting method [PMID: 26502061]
U-937 IC50 150 nM Inhibition of LPS-induced TNFalpha production in human U937 cells preincubated for 1 hr followed by LPS addition measured after 4 hrs by electro-chemiluminescence method [PMID: 26502061]
U-937 IC50 201 nM Inhibition of MK2 in human U937 cells assessed as reduction in LPS-stimulated HSP27 phosphorylation at Ser82 preincubated for 1 hr followed by LPS addition measured after 30 mins by Western blot analysis [PMID: 26502061]

PF-3644022 Research Summary

This section summarizes 4 in vitro studies of PF-3644022 from 3 published references. In vitro models include A549 cells; AG07719A cells.

PF-3644022 In Vitro Studies

In A549 cells, PF-3644022 pretreatment effectively prevented SRC-3 phosphorylation at S857 following TNF-α or anisomycin stimulation. In senescent AG07719A cells, PF-3644022 slightly reduced IL-6 levels at 1.0 µM and 2.5 µM but had no effect at 5 µM. In IL‐33-stimulated BMMCs, inhibitor pretreatment inhibited TNF, IL‐6, IL‐13 and GM‐CSF production compared with the stimulated condition without inhibitor. In a separate A549 experiment, PF-3644022 significantly decreased TNF-α-induced IL-6 promoter-dependent luciferase activity compared with DMSO. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced stimulus-induced SRC-3 phosphorylation in lung cells

Cell-based study · A549 cells [1]

A549 cells were pretreated with PF-3644022 before stimulation with TNF-α or anisomycin, with DMSO as control. PF-3644022 effectively prevented phosphorylation of SRC-3 at S857.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
level of phosphorylation of SRC-3 at S857Reported result The cells were pretreated with DMSO or 1, 2.5, 5, 10 μM of PF-3644022 for 30 min followed by stimulation with either 10 ng/ml TNF-α (C) or 10 μg/ml anisomycin (D) for 30 min. PF-3644022 effectively prevented the phosphorylation of SRC-3 at S857.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 2.5, 5, 10 μM
Exposure duration
for 30 min followed by stimulation with either 10 ng/ml TNF-α (C) or 10 μg/ml anisomycin (D) for 30 min
Method
pretreated
Vehicle
DMSO
Co-treatment
Other interventions in this design: TNF-α 10 ng/ml. Compound effect isolated by the comparison: DMSO or 1, 2.5, 5, 10 μM of PF-3644022.
Methods and source locations

Compound reported in the paper: PF-3644022

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Phosphorylation of SRC-3 at S857 is dependent on MK2 (S54); Figure 4 legend (S248, S249)

level of phosphorylation of SRC-3 at S857: level of phosphorylation of SRC-3 at S857; comparator: DMSO — Results > Phosphorylation of SRC-3 at S857 is dependent on MK2 (S54); Figure 4 legend (S249)

IL-6 levels in inhibitor-treated senescent cells

Cell-based study · AG07719A cells [2]

For AG07719A cells, PF-3644022 had no effect on IL-6 levels when used at 5 µM, but reduced IL-6 levels slightly when used at 1.0 and 2.5 µM. The data refer to inhibitor-treated senescent cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-6 levels (normalised to the cell number and expressed as pg/ml medium per 30,000 cells)Reported result Inhibitor-treated senescent cells: For AG07719A cells, PF-3644022 had no effect on IL-6 levels when used at 5 µM, but reduced IL-6 levels slightly when used at 1.0 and 2.5 µM.[2]

Literature-Reported Treatment Conditions

Treatment concentration
1.0 µM, 2.5 µM and 5 µM
Exposure duration
the inhibitors being present throughout the experiment and replaced at each medium change
Method
the culture medium was supplemented with the inhibitor dissolved in DMSO
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: PF-3644022

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Conditioned medium collection and SASP assay (S18, S20); Results > Suppression of the SASP using p38 inhibitors (S47); Results > Suppression of the SASP using MK2 inhibitors (S55); Fig. 3 legend (S72)

IL-6 levels (normalised to the cell number and expressed as pg/ml medium per 30,000 cells): IL-6 levels (normalised to the cell number and expressed as pg/ml medium per 30,000 cells); comparator: an equivalent volume of the solvent DMSO was added to the medium at a final concentration of 0.1 % (v/v) — Results > Suppression of the SASP using p38 inhibitors (S47); Results > Suppression of the SASP using MK2 inhibitors (S55); Fig. 3 legend (S72)

Inhibition of cytokine production in stimulated BMMCs

Cell-based study · BMMCs [3]

BMMCs were pretreated with the inhibitor at 5 μm before IL‐33 stimulation. Compared with the stimulated condition without inhibitor, treatment inhibited production of TNF, IL‐6, IL‐13 and GM‐CSF.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TNF, IL‐6, IL‐13 and GM‐CSF secreted into the mediaReported result inhibited the production of TNF, IL‐6, IL‐13 and GM‐CSF[3]

Literature-Reported Treatment Conditions

Treatment concentration
5 μm
Exposure duration
for 1 h as shown and then either left unstimulated or stimulated with 10 ng mL−1 IL‐33 for 8 h
Method
pretreated
Vehicle
DMSO
Co-treatment
Other interventions in this design: IL‐33 10 ng mL−1. Compound effect isolated by the comparison: no inhibitor, IL‐33 stimulated condition.
Methods and source locations

Compound reported in the paper: PF-3644022

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > IL‐33‐induced cytokine production requires the p38‐activated kinases MK2 and MK3 (S32); Methods > Cell culture (S117); Figure 2 legend (S178, S180, S181, S183)

TNF, IL‐6, IL‐13 and GM‐CSF secreted into the media: TNF, IL‐6, IL‐13 and GM‐CSF secreted into the media; comparator: no inhibitor, IL‐33 stimulated condition — Results > IL‐33‐induced cytokine production requires the p38‐activated kinases MK2 and MK3 (S32); Figure 2 legend (S181)

Reduced TNF-α-induced promoter-dependent luciferase activity in A549 cells

Cell-based study · A549 cells [1]

A549 cells received PF-3644022 pretreatment at 10 μM, with DMSO as control. TNF-α-induced IL-6 promoter-dependent luciferase activity decreased significantly with treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-6 promoter-dependent luciferaseReported result TNF-α-induced luciferase activity decreased significantly when MK2 activity was inhibited[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
after 48 h treated for 30 min
Method
pretreatment
Vehicle
DMSO
Co-treatment
Other interventions in this design: TNF-α; pGL3-IL-6-promoter vector 120 ng. Compound effect isolated by the comparison: either the MK2 inhibitor PF-3644022, or DMSO as control.
Methods and source locations

Compound reported in the paper: PF-3644022

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > SRC-3 is required for MK2-mediated induction of IL-6 mRNA expression in response to TNF-α (S101, S102, S103); Figure 8 legend (S310)

IL-6 promoter-dependent luciferase: IL-6 promoter-dependent luciferase; comparator: 0.2 μl DMSO — Results > SRC-3 is required for MK2-mediated induction of IL-6 mRNA expression in response to TNF-α (S101, S103)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1276121-88-0
Applications MK2 Inhibitor
Formula C21H18N4OS
Molecular Weight 374.46
SMILES
CC1=NC=C(C2=NC(C=CC(S3)=C4C5=C3C(O)=N[C@](CN5)([H])C)=C4C=C2)C=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PF-3644022 Research References

  1. [1] Shrestha A, Bruckmueller H, Kildalsen H, et al. Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38MAPK-MK2 axis and affects NF-κB-mediated transcription. Sci Rep (2020). PMID: 32647362 DOI: 10.1038/s41598-020-68219-4 Source material
  2. [2] Alimbetov D, Davis T, Brook AJ, et al. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2. Biogerontology (2016). PMID: 26400758 DOI: 10.1007/s10522-015-9610-z Source material
  3. [3] McCarthy PC, Phair IR, Greger C, et al. IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2/3. Immunol Cell Biol (2019). PMID: 30171775 DOI: 10.1111/imcb.12200 Source material

Added to your cart

View Cart Checkout
Loading...